Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> ASTRAZENECA Latest News

MAR 20, 2015 - Zacks Investment Research

A Must Read - Share

AstraZeneca, Daiichi Sankyo to Co-Market Movantik in U.S. - Analyst Blog

AstraZeneca (AZN) inked a deal with Daiichi Sankyo, Inc. for the co-promotion of constipation drug Movantik (EU trade name: Moventig) in the U.S.

Tags: AstraZeneca, Daiichi Sankyo to Co-Market Movantik in U.S. - Analyst Blog,  Astrazeneca Latest News

MAR 19, 2015 - Zacks Investment Research

A Must Read - Share

AstraZeneca Up on Positive Late-Stage Lung Disease Results - Analyst Blog

AstraZeneca's (AZN) respiratory candidate, PT003, being developed for the treatment of chronic obstructive pulmonary disease, is found positive in late-stage PINNACLE studies.

Tags: AstraZeneca Up on Positive Late-Stage Lung Disease Results - Analyst Blog,  Astrazeneca Latest News

MAR 19, 2015 - Wall Street Journal

A Must Read - Share

AstraZeneca, Daiichi Sankyo to Sell Constipation Drug in U.S.

AstraZeneca will partner with the U.S. unit of Daiichi Sankyo to launch constipation drug Movantik in the U.S. early next month, under a deal potentially valued at up to $825 million.

Tags: AstraZeneca, Daiichi Sankyo to Sell Constipation Drug in U.S.,  Astrazeneca Latest News

MAR 18, 2015 - Zacks Investment Research

A Must Read - Share

AstraZeneca Presents Encouraging Heart Drug Brilinta Data - Analyst Blog

AstraZeneca (AZN) presented results from the PEGASUS-TIMI 54 study on Brilinta, showing that long-term treatment with the drug reduced thrombotic cardiovascular events in patients having a history of heart attack.

Tags: AstraZeneca Presents Encouraging Heart Drug Brilinta Data - Analyst Blog,  Astrazeneca Latest News

MAR 18, 2015 - Benzinga

A Must Read - Share

AstraZeneca Announces Positive Phase III Top-line Results for PT003 from PINNACLE 1, PINNACLE 2 Studies in COPD

AstraZeneca (NYSE: AZN) today announced positive top-line results from the Phase III PINNACLE programme, which included two pivotal 24-week studies (PINNACLE 1 and PINNACLE 2) to investigate the potential of PT003 to improve lung function in patients with Chronic Obstructive Pulmonary Disease (COPD).

Tags: AstraZeneca Announces Positive Phase III Top-line Results for PT003 from PINNACLE 1, PINNACLE 2 Studies in COPD,  Astrazeneca Latest News